Contributions
Abstract: EP1675
Type: ePoster
Abstract Category: Therapy - disease modifying - 27 Neuroprotection and Repair
Relapsing Remitting Multiple Sclerosis (RRMS) is an increasingly prevalent condition. Treatments to date have focused on stabilising the inflammatory aspect of disease and maintaining current level of function. Alemtuzumab (Lemtrada®) an anti-CD52 monoclonal antibody is known to reduce disease activity and disability accumulation in primary drug trials. The Australian MS population is a unique demographic to study as there are no barriers to access or funding for any of the highly effective therapies at any stage of the MS disease process.
Aim: To assess the treatment effect of Alemtuzumab for RRMS in an Australian centre, and ascertain if patient outcomes are improved with this new aggressive therapy.
Hypothesis: Patients with an EDSS (Expanded Disability Scoring Status) of 3-4.5 are likely to develop increasing disability from RRMS and will benefit most from new aggressive treatments.
Methods: 15 patients were treated for RRMS at Alfred Health with Alemtuzumab and followed up between 2 and 15 months (average 8 months) with clinical review and EDSS assessment. There were 11 females and 4 males with an average MS disease duration of 7 years.
Results: The average EDSS score prior to commencement of Alemtuzumab was 6.1. The average EDSS following treatment was 2.73 revealing that patients treated with Alemtuzumab had an average EDSS reversal of 3.4. All the patients were treated with highly effective MS therapies prior to Alemtuzumab treatment. Most patients changed to Alemtuzumab due to long term safety concerns with their previous therapies and not because of ongoing MS disease activity.
Additional sub-group analysis determined that patients with a pre-treatment EDSS between 3 and 4.5 had the greatest EDSS reversal compared to those with a pre-treatment EDSS < 2.5 or >6 where there was no significant change in EDSS. All patients had EDSS stabilisation following treatment.
Conclusion: All patients in this study received highly effective MS treatment prior to Alemtuzumab. This new therapy not only stabilised EDSS scores, but in several cases lead do EDSS reversal. Our single centre experience suggests patients with EDSS scores of 3-4.5 are most at risk of accumulating disability and the most likely to positively respond to this new aggressive therapy.
Disclosure:
Dr Skibina and Dr Nesbitt have both previously received sponsorship from Genzyme to attend educational meetings
There are no additional meaningful disclosures
Abstract: EP1675
Type: ePoster
Abstract Category: Therapy - disease modifying - 27 Neuroprotection and Repair
Relapsing Remitting Multiple Sclerosis (RRMS) is an increasingly prevalent condition. Treatments to date have focused on stabilising the inflammatory aspect of disease and maintaining current level of function. Alemtuzumab (Lemtrada®) an anti-CD52 monoclonal antibody is known to reduce disease activity and disability accumulation in primary drug trials. The Australian MS population is a unique demographic to study as there are no barriers to access or funding for any of the highly effective therapies at any stage of the MS disease process.
Aim: To assess the treatment effect of Alemtuzumab for RRMS in an Australian centre, and ascertain if patient outcomes are improved with this new aggressive therapy.
Hypothesis: Patients with an EDSS (Expanded Disability Scoring Status) of 3-4.5 are likely to develop increasing disability from RRMS and will benefit most from new aggressive treatments.
Methods: 15 patients were treated for RRMS at Alfred Health with Alemtuzumab and followed up between 2 and 15 months (average 8 months) with clinical review and EDSS assessment. There were 11 females and 4 males with an average MS disease duration of 7 years.
Results: The average EDSS score prior to commencement of Alemtuzumab was 6.1. The average EDSS following treatment was 2.73 revealing that patients treated with Alemtuzumab had an average EDSS reversal of 3.4. All the patients were treated with highly effective MS therapies prior to Alemtuzumab treatment. Most patients changed to Alemtuzumab due to long term safety concerns with their previous therapies and not because of ongoing MS disease activity.
Additional sub-group analysis determined that patients with a pre-treatment EDSS between 3 and 4.5 had the greatest EDSS reversal compared to those with a pre-treatment EDSS < 2.5 or >6 where there was no significant change in EDSS. All patients had EDSS stabilisation following treatment.
Conclusion: All patients in this study received highly effective MS treatment prior to Alemtuzumab. This new therapy not only stabilised EDSS scores, but in several cases lead do EDSS reversal. Our single centre experience suggests patients with EDSS scores of 3-4.5 are most at risk of accumulating disability and the most likely to positively respond to this new aggressive therapy.
Disclosure:
Dr Skibina and Dr Nesbitt have both previously received sponsorship from Genzyme to attend educational meetings
There are no additional meaningful disclosures